Treatment Approaches for Metastatic NSCLC

Venue: Online Event

Location: Boston, United States

Event Date/Time: Jul 08, 2009 End Date/Time: Jul 08, 2010
Report as Spam


Lung cancer is the leading cause of cancer related mortality in the United States in both men and women. NSCLC accounts for approximately 87% of all new lung cancer diagnoses and the majority of patients either present with incurable disease or relapse after curative therapy leading to the dismal 5 year survival of only 16%.

The management of metastatic NSCLC has evolved a great deal over the last decade and novel therapeutics, combined with chemotherapy, are now the standard of care for patients with newly diagnosed disease. In addition, we have learned a great deal about the role of tumor histology and cancer genetics in predicting responses to both standard chemotherapy and novel agents. Lastly, the role of second line chemotherapy is expanding as we are discovering the potential benefits of its earlier administration.

Learning Objectives:

1. Select patients who are appropriate for novel therapeutics in combination with standard chemotherapy for first line therapy of metastatic NSCLC.

2. Evaluate the potential pros and cons of early second line chemotherapy in metastatic NSCLC.

3. Recognize the impact of histology on the use of both novel therapeutics and standard chemotherapy in patients with metastatic NSCLC.

4. Summarize the implications of genetic testing for predicting response to novel therapeutics in patients with metastatic NSCLC.